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Abstract Standard imaging in acute stroke enables the exclu-
sion of non-stroke structural CNS lesions and cerebral haem-
orrhage from clinical and pre-clinical ischaemic stroke trials.
In this review, the potential benefit of imaging (e.g., angiog-
raphy and penumbral imaging) as a translational tool for trial
recruitment and the use of imaging endpoints are discussed for
both clinical and pre-clinical stroke research. The addition of
advanced imaging to identify a Bresponder^ population leads
to reduced sample size for any given effect size in phase 2
trials and is a potentially cost-efficient means of testing inter-
ventions. In pre-clinical studies, technical failures (failed or
incomplete vessel occlusion, cerebral haemorrhage) can be
excluded early and continuous multimodal imaging of the
animal from stroke onset is feasible. Pre- and post-
intervention repeat scans provide real time assessment of the
intervention over the first 4–6 h. Negative aspects of advanced
imaging in animal studies include increased time under gen-
eral anaesthesia, and, as in clinical studies, a delay in starting
the intervention. In clinical phase 3 trial designs, the negative
aspects of advanced imaging in patient selection include
higher exclusion rates, slower recruitment, overestimated ef-
fect size and longer acquisition times. Imaging may identify
biological effects with smaller sample size and at earlier time
points, compared to standard clinical assessments, and can be
adjusted for baseline parameters. Mechanistic insights can be
obtained. Pre-clinically, multimodal imaging can non-
invasively generate data on a range of parameters, allowing
the animal to be recovered for subsequent behavioural testing
and/or the brain taken for further molecular or histological
analysis.
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Introduction
Stroke is a clinical syndrome that has diverse causes, and
imaging is an essential component of diagnosis. At the most
basic level, brain imaging must distinguish intracerebral
haemorrhage (ICH) from ischaemic stroke, since this cannot
be recognised reliably on clinical grounds alone [1]. As imag-
ing methods have evolved, information on key structural and
physiological features has become widely available and many
imaging techniques are now part of routine clinical care.
Others are employed in clinical trials either for enhancing
patient selection or as a biomarker of outcome. This review
will focus on uses of imaging as a translational tool.
Brain parenchymal imaging with computed tomography
(CT) or magnetic resonance imaging (MRI) forms the main-
stay of clinical imaging. Radionuclide-based methods such as
single-photon emission computed tomography (SPECT) or
positron emission tomography (PET) offer specific physiolog-
ical and molecular imaging techniques suitable for research,
but radiation exposure and long acquisition and analysis times
make these methods unsuited to acute clinical use.
Two main aspects of imaging are of importance in clinical
studies: techniques that give an index of the ischaemic pen-
umbra (and its related parameter, the ischaemic core) and im-
aging of the vasculature.
The concept of the penumbra as originally described by
Astrup, Siesjo and Symon [2] related reduction in cerebral
blood flow to loss of electrical activity and tissue viability
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and defined the concept of perfusion thresholds distinguishing
reversible from irreversible loss of neuronal function.
Subsequent human PET studies translated these concepts into
the relationship between cerebral blood flow and the metabol-
ic rate for oxygen [3]. These concepts can be translated to CT
and MRI [4, 5]. In general, the non-viable ischaemic core on
MRI corresponds to tissue with reduced apparent diffusion
coefficient (ADC) of water, consequent to failure of energy-
dependent membrane ion exchange and shift of interstitial
water to the intracellular compartment. Reduced ADC is
visualised clinically as a diffusion-weighted image (DWI).
The DWI lesion on MRI corresponds closely to reduced ce-
rebral blood flow (CBF) or cerebral blood volume (CBV) on
perfusion imaging, either with MR (MRP) or with CT perfu-
sion (CTP). The ischaemic penumbra corresponds to tissue
that has less severe reduction of perfusion, and although elec-
trically inactive (and thus causing clinical symptoms) remains
viable for a period of minutes to hours if reperfused [6]. The
penumbra therefore is hypoperfused, but exhibits less severe
reductions in CBF, and preserved or increased CBV and nor-
mal DWI. The distinction between functionally impaired pen-
umbra and regions of Bbenign oligaemia^—tissue that exhibits
reduced perfusion but will survive regardless of whether or
not reperfusion occurs—is generally based upon thresholds of
prolonged mean transit time (MTT) or delayed time to peak
(TTP) in contrast-based perfusion studies using either MRP or
CTP. Definitions of these tissue compartments—core, penum-
bra and benign oligaemia—depend upon the imaging tech-
nique and the selection of threshold values. Most studies to
define thresholds have been of small or modest size, and it is
therefore unsurprising that proposed thresholds have varied
across different studies and different times [7]. It is likely that
the thresholds themselves vary according to the duration of
ischaemia [8].
Vascular imaging with CT or MR angiography (CTA or
MRA) can identify the presence of extracranial stenosis, the
presence of intracranial thrombotic occlusion in large vessels
(typically out to the third order branches of the middle cerebral
artery [MCA]) and the extent of primary and leptomeningeal
collaterals.
Advantages and Disadvantages of Imaging
in Clinical Trial Design
Inclusion of patients who lack a relevant biological target for a
given intervention has a significant impact on sample size in
clinical trials due to the dilution of the target responder group.
As the proportion of patients with no relevant biological target
increases, so the sample size increases markedly [9]. For
illustration, a 25 % relative reduction in poor outcome might
require a sample size of 390 per group if all patients have a
biological target, but this rises to 920 per group if only 65 %
have a relevant target [9]. In phase 2 clinical trials, sample size
is generally small and it is particularly important to explore
issues around treatment response of different groups. Imaging
allows better characterisation of clinical populations than clin-
ical criteria alone, and its use at this stage of research is rec-
ommended [10]. Clinical criteria try to exclude non-stroke
diagnoses (e.g., seizures and hypoglycaemia), and basic im-
aging excludes some non-stroke structural central nervous
system lesions. Other imaging features may be regarded as a
prerequisite for patient selection in specific scenarios, such as
the requirement for an arterial occlusion in a suitable target
vessel in trials of endovascular mechanical thrombectomy
(MT), as discussed below.
In ischaemic stroke, the penumbra is postulated to repre-
sent the therapeutic target for reperfusion or neuroprotectant
therapies and penumbral imaging selection is expected to re-
duce sample size, by ensuring that all recruited subjects have a
relevant biological target. The penalty of more stringent selec-
tion criteria is a greater exclusion rate and thus slower recruit-
ment [9]. Based on limited imaging data available more than a
decade ago, an estimated 5–7 % of clinically eligible patients
were predicted to fulfil parenchymal imaging selection criteria
(thus increasing the Bnumber needed to screen^ per trial recruit
to 16–20, but ensuring an informative population). In the
EXTEND-IA trial [11], 70/1044 (7 %) of those patients eligi-
ble for intravenous (IV) thrombolysis were selected for
randomisation to additional MT or best medical care.
Imaging criteria excluded a high proportion of patients,
around half due to absence of relevant vessel occlusion and a
quarter of those with vessel occlusion due to unfavourable
perfusion imaging, suggesting that estimates for the potential
impact on recruitment rates were close to reality.
Two recent phase 2 trials comparing the thrombolytic agent
tenecteplase with the standard of care rtPA alteplase illustrate
the advantages and disadvantages of imaging selection and
endpoints. Parsons and colleagues applied imaging selection
criteria including presence of CTA-defined arterial occlusion,
minimum penumbra volume and maximum core volume,
achieving a relatively homogeneous trial population and find-
ing tenecteplase superior to alteplase on both clinical and im-
aging endpoints [12]. The ATTEST trial [13] acquired CTA
and CTP but used only CT and clinical criteria to define eli-
gibility, resulting in a more heterogeneous population.
ATTEST did not demonstrate any difference in clinical or
imaging outcomes. Parsons’ imaging selection criteria exclud-
ed 79 % of rtPA-eligible patients, and only 12 % of treatment-
eligible patients were randomised, compared to 66 % of pa-
tients in ATTEST. In translating results from such focused
phase 2 trials, phase 3 trials face the challenge of es-
tablishing generalisability in settings where complex im-
aging is less likely to be available, but absolute effect
sizes are likely to be overestimated based on highly
selected phase 2 findings.
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Angiographic Imaging
The third Interventional Management of Stroke (IMS-3) trial
[14] tested the value of additionalMTamongst patients treated
with IV thrombolysis with recombinant tissue plasminogen
activator (rtPA), but did not identify any significant benefit
of MT compared to IV rtPA alone. The IMS-3 trial started
when CTA was not available routinely, and consequently a
majority of patients (53 %) randomised in the trial were found
to have no relevant arterial occlusion when undergoing initial
angiography for MT. Of those having CTA or MRA, when
these became adopted into clinical practice during the course
of the trial, 8 % had no arterial occlusion and a further 20 %
had isolated distal vessel occlusion (beyond the size of target
vessel for the interventions being undertaken). It is therefore
likely that at least one third of those patients eligible on clin-
ical criteria would have been excluded on the basis of CTA. In
addition, a proportion of patients is found to have already
reperfused between randomisation and the start of the
endovascular procedure, (11% in the recent EXTEND-IA trial
[11]) emphasising that vessel status (and presumably also tis-
sue status) is a dynamic phenomenon in the acute phase of
stroke and that eligibility may fluctuate. A subgroup analysis
of IMS-3 that included only those patients with confirmed
large artery occlusion on CTA where it was available found
a trend towards benefit for additional MT [15].
All subsequent (positive) trials of MT have required the
presence of a relevant occlusion on non-invasive imaging,
predominantly CTA. Limiting invasive procedures to those
with relevant large artery occlusion is both ethically appropri-
ate and maximises trial efficiency. The appropriate treatment
target may, of course, vary according to the intervention being
tested. Eligibility for MT is readily defined by widely avail-
able non-invasive investigation; for other interventions, how-
ever, this might be less readily identified and the danger is that
focus on a group with a logical target excludes patients who
might derive benefit through mechanisms that are not initially
understood. A secondary analysis of the combined data from
the EPITHET trial and observational DEFUSE study reported
greater benefit of thrombolysis in the presence of a visible
arterial occlusion on MRA [16]. It may therefore be that
imaging-defined arterial occlusion represents a target popula-
tion for reperfusion therapies in general. Since the majority of
major trials of intravenous thrombolysis were undertaken
without vascular imaging, it is not possible to define whether
the benefit of IV thrombolysis differs amongst those without
visible occlusion.
Perfusion Imaging
Observational data suggest that reperfusion confers clear ben-
efit amongst those with variously defined penumbral imaging
patterns on either MRI or CT, whereas reperfusion does not
have a clear benefit amongst those without such a pattern
[17–19]. In some studies, the time window for potential ben-
efit from reperfusion appeared longer than that based from
conventional imaging alone, supporting study designs that
are investigating the potential efficacy of reperfusion in
imaging-selected patients at later time points [20]. The num-
ber of subjects included in these observational studies, how-
ever, is small; in DEFUSE-2, only 21 patients contributed to
the Bno target mismatch^ group [17]. These patients were
already highly selected by being considered eligible for
endovascular MT and also being MRI-compatible, and
generalisability of these observations is accordingly unclear.
In part, the differences in outcome in observational studies
may be explainable by the reduced risk of symptomatic intra-
cerebral haemorrhage (SICH) when those patients with Blarge
core^ profiles on imaging are excluded. Large ischaemic core
lesions (defined by DWI lesion, reduced CBF or CBV, or
hypoattenuation on CT) generally exceed 50 or 70 ml in vol-
ume. The Alberta Stroke Programme Early CT [ASPECT]
score offers an alternative for non-contrast CT. An ASPECT
score <7was used to exclude large core patients in several recent
endovascular trials. Possible increased risk of SICHwhen reper-
fusion occurs in patients with MRI-defined Blarge core^ has
been reported in the DEFUSE and EPITHET datasets [21].
CTP-defined large core is associated with higher incidence of
ICH regardless of reperfusion [22]. Reduced incidence of SICH
has been reported in observational cohorts with both MRI [23]
and with perfusion CT [19], but definitions of core have been
variable [7, 24, 25] and standard criteria are not yet agreed.
Several trials propose that the Bpenumbral^ or Btarget
mismatch^ pattern on imaging defines the presence of viable
tissue in a largely time-independent manner, viable tissue
persisting for longer periods than the conventional treatment win-
dow for IV thrombolysis for example. Trial designs have there-
fore sought to select patients with penumbral imaging patterns at
late time points (e.g., 3–9 h after symptom onset in the DIAS and
DEDAS trials [26, 27], 4.5–9 h in the ongoing ECASS-4 and
EXTEND trials). Issues with consistency of imaging processing
and interpretation across multiple sites with different approaches
to scanning have confounded these studies [7, 20–30].
Penumbral imaging parameters have been used in three
recent MT trials to select patients as a means of minimising
the sample size by excluding those with very favourable or
very poor prognosis [11, 12, 26–28, 30, 31], a concept pro-
posed originally from PET observations [3]. The SWIFT-
Prime [31] and EXTEND-IA [11] trials used perfusion imaging
(predominantly CTP) and ESCAPE [32] using multiphase
collateral vessel imaging. These three trials found larger effect
sizes compared to the twoMT trials that used only CTand CTA
for selection,MRCLEAN [33] and REVASCAT [34] (Table 1).
Reliable evidence that parenchymal imaging parameters
modify the treatment effect of a given intervention is,
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however, lacking and indeed, in the few trials that have ac-
quired complex imaging but not used imaging selection pa-
rameters, there was no evidence of a differential treatment
effect [33, 35–38]. This was evident most recently from the
CTP subgroup analysis of the MR CLEAN trial, where CTP
was acquired in 175/500 (35 %) patients but not used explic-
itly to select patients. Secondary analysis identified no hetero-
geneity of the treatment effect of MT with any perfusion pa-
rameter [38]. It is possible that this may reflect a dominant
effect of very early reperfusion and that selection by penum-
bral imaging might be of greater value in later time windows.
The MR CLEAN sub-study emphasised a further concern
that despite acquisition in most patients (67 % in all), data
could not be analysed due to technical limitations in more than
one third of cases. Since technical factors such as motion ar-
tefacts and premature truncation of the venous outflow curve
are more likely in those with greater stroke severity, there may
be additional selection bias introduced. Disagreement between
local observers’ interpretation of perfusion scans and central
Bexpert^ interpretation is also common, even in highly expe-
rienced centres [19]: in an observational cohort study using
CTP to select patients for IV thrombolysis, 25 % of patients
were inappropriately excluded from IV rtPA on the basis of
discrepant CTP interpretation and conversely 27 % who
should have been excluded were treated with IV rtPA. The
lack of standardisation for perfusion imaging has been well
documented [7, 25] and is considered to have contributed to
the failure of at least two clinical trials [28–30].
Imaging as a Selection Tool in the Absence of Clinical
Information
Imaging may provide information about onset time when clin-
ical history is unable to, for example the 25 % of patients who
wake with symptoms, or those unable to give a history
because of dysphasia or conscious level reduction and no
witness.
The ongoing WAKE-UP trial [39] uses the difference in
signal intensity between diffusion-weighted MRI (immediate
signal change due to cytotoxic oedema) and T2 FLAIR
(slower and gradual change as vasogenic oedema develops)
to identify likely onset of ischaemia in the preceding 4.5 h and
selects patients with this pattern to be randomised to IV rtPA
or placebo [40]. Similar proposals using non-contrast CT have
been advanced [40, 41]. Time-independent imaging parame-
ters, such as a presence of a penumbral pattern on CTP, are
utilised in the current ECASS-4 and EXTEND trials [42],
which enrol stroke of unknown onset time (in addition to those
clearly presenting in the 4.5–9-h time window).
Imaging as an Explanatory Factor rather than
Selection Filter
Imaging features such as large ischaemic core, poor
leptomeningeal collateral vessels, volume of hypoattenuation
on non-contrast CT, volume of tissue with very severe hypo-
perfusion [43] or perfusion lesion volume [44] are strongly
predictive of outcome and independent of clinical features.
Characterising the site of arterial occlusion, penumbra and
core volumes in the phase 2 Alteplase-Tenecteplase Trial for
Efficacy in Stroke Thrombolysis (ATTEST) study offered in-
sights into chance imbalances between treatment groups that
were not apparent from the clinical assessments alone [13].
Acquisition of advanced penumbral and vascular imaging also
allows pooling of data with other phase 2 studies that share
similar imaging protocols. It is therefore a recommendation of
the STAIR Imaging Roadmap meeting that phase 2 trials in
acute stroke should wherever feasible gather such data. Trials
where imaging has been acquired but not used to select pa-
tients, such as in ATTEST, may offer a more generalizable
Table 1 Effect sizes in published endovascular thrombectomy trials
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Table 2 Clinical summary
Earlier and  more speciﬁc idenﬁcaon
of biological eﬀect compared to
clinical assessment
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treatment effect estimate to take forward to phase 3 trials, as
well as suggesting selection criteria that might be utilised to
maximise trial efficiency. More highly selected patient groups,
such as studied in the Australian phase 2 tenecteplase trial
[12], can achieve highly encouraging results from small sam-
ple sizes, but inevitably overestimate the absolute effect size
that would be seen in a less selected population.
Imaging as an Endpoint in Clinical Trials
Whilst day 90 or later time points are generally used for clin-
ical outcome assessment, efficacy measures that can provide
earlier information are valuable in many clinical trial designs.
Imaging biomarkers may be particularly valuable in dose-
finding studies with an adaptive design, where ineffective or
unsafe doses can be discarded during the conduct of the trial as
data accrue. An early example of this approach was a phase
2/3 trial of tenecteplase that compared three different
tenecteplase doses against a standard alteplase (rtPA) dose
[45], using early clinical improvement and 24-h CT safety
outcome (incidence of SICH) to guide dose selection dynam-
ically. Alternative imaging metrics have been proposed, in-
cluding Bfinal^ infarct volume on MRI [46], reperfusion
[12] or early recanalization.
The incidence of ICH on follow-up imaging has been a key
safety parameter in trials of thrombolysis or reperfusion. Brain
oedema is another safety parameter that has been reported
only infrequently.
There are significant difficulties with several proposed im-
aging biomarkers. Selection bias, as noted above, is an issue.
Patients with exclusions based on safety in MRI or in relation
to contrast agent administration, those who do not tolerate
imaging, or who die before follow-up imaging are all exclud-
ed from recruitment, analysis or both. There is a significant
inter-observer variability in measurement of volume parame-
ters, worse for CT than for MRI [47], and the occurrence of
brain swelling, intracerebral haemorrhage and presence of
established background ischaemic changes may both obscure
any volumetric assessment and vary according to the time of
follow-up imaging acquisition. Very late Boutcome^ imaging
is confounded by tissue atrophy.
A summary of the main points for and against the use of
MRI for stroke patient selection and stroke endpoints is
displayed in Table 2 on previous page.
Pre-clinical
Scaled down equipment exists for small animal imaging using
PET, MRI and functional ultrasound. MRI is currently the
most commonly used technique offering non-invasive multi-
modal imaging with good resolution and without the need for
ionising radiation. The range of sequences available and the
ability to scan the animal on a number of occasions and repeat
scans over a number of hours within a single scanning session
have provided pre-clinical stroke research with a very power-
ful tool. It has been used to study stroke pathophysiology, to
develop more informative diagnostic imaging and to investi-
gate new therapies targeted at acute and chronic phases of
stroke. MRI imaging available to the basic scientist includes
DWI for ischaemic injury and peri-infarct depolarisations,
perfusion imaging (PI) for perfusion deficits, and combination
of the two for identification of tissue-at-risk, MR spectroscopy
for metabolites of interest, tissue pH and sodium, T2* with
contrast for blood–brain barrier breakdown, T2 for final in-
farct, FLAIR for cerebral haemorrhage, manganese-enhanced
MRI for tagging and tracking injected cells and CNS connec-
tivity studies, diffusion tensor imaging (DTI) for studying
white matter injury and Fluorine 19 MR spectroscopy for
imaging inflammation. Surrogate markers for recovery after
stroke include DTI and T2* for functional MRI (fMRI) and
baseline connectivity studies.
Acute Stroke Imaging—Diffusion-weighted Imaging The
most informative scanning technique in the acute stroke peri-
od must surely be diffusion-weighted imaging (DWI). Using
rodent middle cerebral artery occlusion (MCAO) models, fo-
cal ischaemia can be induced within the scanner and
hyperintensity appears within 10 min of onset, reflecting a
similar timescale to human stroke [48]. One topic of debate
within the literature has been whether the DWI lesion, referred
to as the Bischaemic core,^ reflects irreversibly damaged tis-
sue destined to infarct, or injured tissue, some of which is
capable of recovery when promptly reperfused [49]. Early
hyperintensity, reflecting restricted diffusion of water in the
extracellular compartment, is partially or completely reversed
by prompt restoration of flow through the MCA [50].
Reperfusion-induced reversal of some of the hyperintense le-
sion on DWI scans occurs in rodent stroke models (e.g., 30–
90-min intraluminal filament MCAO) with recovered tissue
showing a normal MR signature on the subsequent T2 images
7 days post-stroke [51, McCabe C, personal communication].
The longer the tissue is exposed to ischaemia, the greater the
certainty that the DWI lesion represents irreversibly damaged
tissue. With maintained MCAO, the intensity and size of the
DWI lesion increases over the first 4–6 h [52] as penumbral
tissue succumbs to the lack of oxygen and nutrients and the
waves of spreading depolarisation that exhaust its remaining
ATP stores [53, 54]. Without intervention, presumed penum-
bral tissue in rodent models (defined from PWI/DWI mis-
match) has a lifespan of around 4–6 h [55]. However, in stud-
ies where anaesthetised, ventilated animals are monitored and
blood pressure and blood gases maintained within normal
limits; scanning over the first 6–7 h after MCAO in some
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studies has revealed minimal DWI lesion growth and
prolonged penumbral lifespan [56, 57].
In pre-clinical stroke research, DWI scans are routinely
processed to produce apparent diffusion coefficient (ADC)
maps. This allows the impedance of water molecule diffusion
in normal and injured tissue to be assigned a quantitative value
(mm2/s) and ADC thresholds applied to provide unbiased as-
sessment of tissue-at-risk of infarction [58]. These ADC
thresholds are derived for specific time points after a
maintained ischaemic insult (permanent MCAO) using
Table 3 Pre-clinical summary
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final infarct volume data on later T2 scans or histology
sections. There is a good agreement amongst different
pre-clinical groups that has established in-house ADC
thresholds (see Table 1 in reference [55]).
When studying new therapeutic interventions, an acute
DWI scan, carried out after stroke onset but before delivering
the therapy or reperfusion, is extremely valuable. It confirms a
successful ischaemic insult in each animal and provides base-
line data of ischaemic damage to assess how an intervention
influences the subsequent evolution of ischaemic damage in
each animal. Given the variability in lesion size observed in
rodent models of MCAO, particularly with the intraluminal
filament model, this allows the effect of treatment/reperfusion
to be more accurately assessed by determining change in le-
sion size between the initial DWI lesion and final infarct,
within each animal.
Acute Stroke Imaging–Angiography and Perfusion
Imaging
In contrast to clinical imaging, contrast-based angiography
and perfusion sequences are rarely used in pre-clinical stroke
research. Instead, non-invasive, non-contrast-enhanced ap-
proaches are used where flowing blood replaces exogenous
contrast agents (e.g., time-of-flight angiography and continu-
ous and pseudo-continuous arterial spin labelling-ASL).
Angiography sequences reveal completeness of MCAO and
quality of reperfusion on subsequent recanalisation of the
MCA in transient MCAO models. This allows failed or in-
complete MCAO to be identified early providing another way
in which variability in drug studies can be controlled.
ASL techniques can provide fully quantitative CBF data
(mL/100 g/min) rather than the delay-based parameters
favoured clinically in the setting of dynamic susceptibility
contrast imaging using gadolinium contrast. By employing
an endogenous contrast agent, serial and repeat assessment
of CBF is possible plus the absence of exogenous contrast
agents means there is no influence on other sequences within
a multimodal scanning protocol. However, ASL sequences
require much longer scanning times than DWI so it is not
always possible to acquire sufficient ASL slices for full cov-
erage of the MCA territory during serial (e.g., hourly) multi-
modal imaging. Few studies have confirmed the accuracy of
the technique on individual scanners [59, 60], and values re-
corded for non-ischaemic (contralateral) CBF following
MCAO in rats show wide variations in CBF values (see
Table 1 in reference [55]).
General anaesthesia (GA) represents an additional compli-
cation and source of variation in CBF values in rodent stroke
studies. GAwill influence blood pressure and in unventilated
animals, respiration and blood gases. These in turn can influ-
ence CBF, particularly in experimental stroke studies where
autoregulation will be impaired. Therefore, in contrast to the
consistency in defining ADC thresholds and the ischaemic
lesion fromDWI scans, there is greater uncertainty in defining
CBF thresholds for assessment of the perfusion deficit from
ASL scans. Problems can be encountered in defining in-house
perfusion thresholds, and published perfusion thresholds
range from 57 to 81 % reduction in flow (see Table 1 in
reference [55]). For example, following permanent MCAO,
visual inspection of colour-coded CBFmaps at 4 h post-stroke
alongside final T2 infarct scans at 24 h can show regions of
severely hypoperfused perfusion deficits which are larger than
the infarct on the same slice, making it problematic to define
perfusion thresholds based on final, oedema-corrected infarct.
It is also likely that CBF in the ischaemic hemisphere will rise
on removal of GA, with collateral flow improving as blood
pressure rises, potentially resetting the boundaries between
normal flow, benign oligaemia, penumbra and ischaemic core.
Serial perfusion imaging (PI) following both permanent
and transient MCAO allows for the assessment of temporal
changes in perfusion following intervention. By combining PI
and ADC maps, the amount of PI/DWI mismatch is used to
assess the lifespan of this Btissue-at-risk^ and the influence of
interventions. It also facilitates the selection of animals to
balance groups prior to randomization and entry into subse-
quent therapy studies.
Acute Stroke Imaging—Determining Tissue Viability
and Stroke Onset Time
Stroke onset time, key in the evaluation and management of
acute stroke patients, is often unavailable. Around 25 % of
patients fall within the Bwake up^ category [61] excluding
them from access to acute reperfusion therapy. Therefore,
pre-clinical research has explored the possibility of imaging
biomarkers which could provide a reasonable estimate of
stroke onset time. One proposed biomarker is brain tissue
sodium concentration (TSC) which appears to increase linear-
ly over time in tissue at risk of infarction with a threshold for
tissue viability close to normal values. Since brain tissue so-
dium can be measured with MRI in man, a single acute stroke
TSC scan could theoretically be used to extrapolate back to
estimate stroke onset time which would coincide with the time
point at which tissue sodium signal starts to rise above normal
[62, 63]. However, subsequent serial animal MRI studies test-
ing this hypothesis found extrapolating ischaemic core data
back in time resulted in differences of >1 hour between actual
stroke onset time and the onset of elevated TSC [57].
Nonetheless, TSC may serve as a useful biomarker of tissue
viability since differing TSC and temporal profiles are present
in ischaemic core (linearly increasing TSC) and penumbra (≤
contralateral TSC) [57]. This could be a useful adjunct to PI/
DWI mismatch, commonly used pre-clinically to identify po-
tentially savageable penumbral tissue but still lacking consen-
sus on the setting of perfusion and diffusion thresholds which
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are also likely to vary according to time from stroke onset.
More direct assessment of tissue viability following stroke has
been proposed by exploiting the T2* BOLD sequence and the
different magnetic properties of oxy- and deoxyhaemoglobin.
When combined with an oxygen challenge, the T2* signal
change (as paramagnetic deoxyhaemoglobin is converted to
diamagnetic oxyhaemoglobin) is greater in penumbra than in
adjacent ischaemic core and normal tissue [64–66]. Since the
basis for increased signal in penumbra is due to an increased
oxygen extraction factor, vascular changes associated with the
change in PaO2, or a combination of the two, this could
represent a more valid method for detection of penumbra.
A summary of the main points for and against the use of
MRI for stroke animal selection and stroke endpoints is
displayed in Table 3 on the previous page.
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